TAK - Oppenheimer cuts Ovid to perform cites uncertainty over lead drug June, 18 2024 12:27 PM Takeda Pharmaceutical Company Limited American Depositary Shares 2024-06-18 12:27:47 ET More on Ovid Therapeutics Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024 Ovid stock plunges 66% on failed studies for soticlestat Ovid Therapeutics gains on bullish view at Wedbush Seeking Alpha’s Quant Rating on Ovid Therapeutics Historical earnings data for Ovid Therapeutics For further details see: Oppenheimer cuts Ovid to perform, cites uncertainty over lead drug